JP2002511850A - 報酬欠損症候群の対立遺伝子多遺伝子診断および処置 - Google Patents
報酬欠損症候群の対立遺伝子多遺伝子診断および処置Info
- Publication number
- JP2002511850A JP2002511850A JP54736498A JP54736498A JP2002511850A JP 2002511850 A JP2002511850 A JP 2002511850A JP 54736498 A JP54736498 A JP 54736498A JP 54736498 A JP54736498 A JP 54736498A JP 2002511850 A JP2002511850 A JP 2002511850A
- Authority
- JP
- Japan
- Prior art keywords
- gene
- allele
- behavior
- rds
- detecting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000003234 polygenic effect Effects 0.000 title claims description 64
- 238000011282 treatment Methods 0.000 title claims description 48
- 208000011580 syndromic disease Diseases 0.000 title claims description 18
- 230000007812 deficiency Effects 0.000 title abstract description 20
- 238000003745 diagnosis Methods 0.000 title description 15
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 claims abstract description 175
- 229960003638 dopamine Drugs 0.000 claims abstract description 88
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 claims abstract description 62
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 59
- 239000002243 precursor Substances 0.000 claims abstract description 50
- 239000000203 mixture Substances 0.000 claims abstract description 49
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 42
- 229940076279 serotonin Drugs 0.000 claims abstract description 28
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 21
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- URLZCHNOLZSCCA-VABKMULXSA-N Leu-enkephalin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 URLZCHNOLZSCCA-VABKMULXSA-N 0.000 claims abstract description 15
- 208000024891 symptom Diseases 0.000 claims abstract description 15
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 10
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims abstract description 10
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims abstract description 9
- 102000009025 Endorphins Human genes 0.000 claims abstract 2
- 108010049140 Endorphins Proteins 0.000 claims abstract 2
- 108090000623 proteins and genes Proteins 0.000 claims description 311
- 108700028369 Alleles Proteins 0.000 claims description 259
- 238000000034 method Methods 0.000 claims description 213
- 230000006399 behavior Effects 0.000 claims description 148
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 128
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 128
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 116
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 102
- 208000035475 disorder Diseases 0.000 claims description 94
- 239000003814 drug Substances 0.000 claims description 85
- 230000000694 effects Effects 0.000 claims description 83
- 229940079593 drug Drugs 0.000 claims description 82
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 71
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 60
- 208000016620 Tourette disease Diseases 0.000 claims description 58
- -1 DβH Proteins 0.000 claims description 57
- 208000008589 Obesity Diseases 0.000 claims description 56
- 235000020824 obesity Nutrition 0.000 claims description 52
- 208000007848 Alcoholism Diseases 0.000 claims description 51
- 208000011117 substance-related disease Diseases 0.000 claims description 50
- 101150049660 DRD2 gene Proteins 0.000 claims description 47
- 230000003542 behavioural effect Effects 0.000 claims description 46
- 102000054765 polymorphisms of proteins Human genes 0.000 claims description 45
- 201000007930 alcohol dependence Diseases 0.000 claims description 44
- 238000003556 assay Methods 0.000 claims description 43
- 230000001965 increasing effect Effects 0.000 claims description 37
- 102100020802 D(1A) dopamine receptor Human genes 0.000 claims description 32
- 101000931925 Homo sapiens D(1A) dopamine receptor Proteins 0.000 claims description 32
- 201000000980 schizophrenia Diseases 0.000 claims description 32
- 230000000391 smoking effect Effects 0.000 claims description 30
- 102100028661 Amine oxidase [flavin-containing] A Human genes 0.000 claims description 29
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 claims description 29
- 239000000126 substance Substances 0.000 claims description 29
- 229940024606 amino acid Drugs 0.000 claims description 28
- 150000001413 amino acids Chemical class 0.000 claims description 27
- 230000004044 response Effects 0.000 claims description 27
- 208000001613 Gambling Diseases 0.000 claims description 26
- 206010013663 drug dependence Diseases 0.000 claims description 25
- 102100029815 D(4) dopamine receptor Human genes 0.000 claims description 24
- 101000865206 Homo sapiens D(4) dopamine receptor Proteins 0.000 claims description 24
- 208000019901 Anxiety disease Diseases 0.000 claims description 23
- 206010026749 Mania Diseases 0.000 claims description 23
- 229940127240 opiate Drugs 0.000 claims description 23
- 102100024959 5-hydroxytryptamine receptor 2C Human genes 0.000 claims description 22
- 101000822895 Homo sapiens 5-hydroxytryptamine receptor 1A Proteins 0.000 claims description 22
- 101000761348 Homo sapiens 5-hydroxytryptamine receptor 2C Proteins 0.000 claims description 22
- 108020002739 Catechol O-methyltransferase Proteins 0.000 claims description 21
- 102100029808 D(3) dopamine receptor Human genes 0.000 claims description 21
- 102000017911 HTR1A Human genes 0.000 claims description 21
- 101000865224 Homo sapiens D(3) dopamine receptor Proteins 0.000 claims description 21
- 230000001976 improved effect Effects 0.000 claims description 21
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 20
- 230000015654 memory Effects 0.000 claims description 20
- 102000017707 GABRB3 Human genes 0.000 claims description 19
- 230000006378 damage Effects 0.000 claims description 19
- 208000024714 major depressive disease Diseases 0.000 claims description 18
- 102100029813 D(1B) dopamine receptor Human genes 0.000 claims description 17
- 102000017694 GABRA3 Human genes 0.000 claims description 17
- 101000865210 Homo sapiens D(1B) dopamine receptor Proteins 0.000 claims description 17
- 101001073597 Homo sapiens Gamma-aminobutyric acid receptor subunit beta-3 Proteins 0.000 claims description 17
- 108010062431 Monoamine oxidase Proteins 0.000 claims description 17
- 208000003028 Stuttering Diseases 0.000 claims description 17
- 229940046374 chromium picolinate Drugs 0.000 claims description 17
- GJYSUGXFENSLOO-UHFFFAOYSA-N chromium;pyridine-2-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1.OC(=O)C1=CC=CC=N1 GJYSUGXFENSLOO-UHFFFAOYSA-N 0.000 claims description 17
- 102100033156 Dopamine beta-hydroxylase Human genes 0.000 claims description 16
- 101710136122 Tryptophan 2,3-dioxygenase Proteins 0.000 claims description 16
- 201000009032 substance abuse Diseases 0.000 claims description 16
- 238000003786 synthesis reaction Methods 0.000 claims description 16
- 101150110160 DRD1 gene Proteins 0.000 claims description 15
- 101000893321 Homo sapiens Gamma-aminobutyric acid receptor subunit alpha-3 Proteins 0.000 claims description 15
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 15
- 101150089079 PS1 gene Proteins 0.000 claims description 15
- 230000013016 learning Effects 0.000 claims description 15
- 102100022645 Glutamate receptor ionotropic, NMDA 1 Human genes 0.000 claims description 14
- 108010054235 NMDA receptor A1 Proteins 0.000 claims description 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 14
- 208000019116 sleep disease Diseases 0.000 claims description 14
- 101000927562 Homo sapiens Dopamine beta-hydroxylase Proteins 0.000 claims description 13
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 claims description 13
- 101150087313 Cd8a gene Proteins 0.000 claims description 12
- 101150076975 DAT1 gene Proteins 0.000 claims description 12
- 208000010235 Food Addiction Diseases 0.000 claims description 12
- 108091092878 Microsatellite Proteins 0.000 claims description 12
- 102100038931 Proenkephalin-A Human genes 0.000 claims description 12
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 claims description 12
- 230000036506 anxiety Effects 0.000 claims description 12
- 102100036321 5-hydroxytryptamine receptor 2A Human genes 0.000 claims description 11
- 206010003805 Autism Diseases 0.000 claims description 11
- 208000020706 Autistic disease Diseases 0.000 claims description 11
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 claims description 11
- 208000022497 Cocaine-Related disease Diseases 0.000 claims description 11
- 101000783617 Homo sapiens 5-hydroxytryptamine receptor 2A Proteins 0.000 claims description 11
- 208000028017 Psychotic disease Diseases 0.000 claims description 11
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 claims description 11
- 230000016571 aggressive behavior Effects 0.000 claims description 11
- 229960004799 tryptophan Drugs 0.000 claims description 11
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims description 10
- 235000002637 Nicotiana tabacum Nutrition 0.000 claims description 10
- HPCCGRCEBFBZQP-UHFFFAOYSA-N chromium;pyridine-3-carboxylic acid Chemical compound [Cr].OC(=O)C1=CC=CN=C1 HPCCGRCEBFBZQP-UHFFFAOYSA-N 0.000 claims description 10
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 230000009329 sexual behaviour Effects 0.000 claims description 10
- 101001099423 Homo sapiens Proenkephalin-A Proteins 0.000 claims description 9
- 108010074328 Interferon-gamma Proteins 0.000 claims description 9
- 241000208125 Nicotiana Species 0.000 claims description 9
- 102000012412 Presenilin-1 Human genes 0.000 claims description 9
- 108010036933 Presenilin-1 Proteins 0.000 claims description 9
- 102000054766 genetic haplotypes Human genes 0.000 claims description 9
- 230000007958 sleep Effects 0.000 claims description 9
- 101150046236 CNR1 gene Proteins 0.000 claims description 8
- 102000008070 Interferon-gamma Human genes 0.000 claims description 8
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 8
- 230000001476 alcoholic effect Effects 0.000 claims description 8
- 230000002255 enzymatic effect Effects 0.000 claims description 8
- 229960003130 interferon gamma Drugs 0.000 claims description 8
- 201000003723 learning disability Diseases 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 229930182816 L-glutamine Natural products 0.000 claims description 7
- 108090000189 Neuropeptides Proteins 0.000 claims description 7
- 101150069775 PENK gene Proteins 0.000 claims description 7
- 206010034158 Pathological gambling Diseases 0.000 claims description 7
- 231100000736 substance abuse Toxicity 0.000 claims description 7
- 101150029129 AR gene Proteins 0.000 claims description 6
- 101150064250 Chrna4 gene Proteins 0.000 claims description 6
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 6
- 102000003797 Neuropeptides Human genes 0.000 claims description 6
- 206010001584 alcohol abuse Diseases 0.000 claims description 6
- 208000025746 alcohol use disease Diseases 0.000 claims description 6
- 201000006145 cocaine dependence Diseases 0.000 claims description 6
- 235000005911 diet Nutrition 0.000 claims description 6
- 230000002969 morbid Effects 0.000 claims description 6
- 230000001537 neural effect Effects 0.000 claims description 6
- 230000001575 pathological effect Effects 0.000 claims description 6
- 208000028173 post-traumatic stress disease Diseases 0.000 claims description 6
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 claims description 5
- 229940000681 5-hydroxytryptophan Drugs 0.000 claims description 5
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 5
- 229930195714 L-glutamate Natural products 0.000 claims description 5
- 108090000028 Neprilysin Proteins 0.000 claims description 5
- 102000003729 Neprilysin Human genes 0.000 claims description 5
- 229960002989 glutamic acid Drugs 0.000 claims description 5
- 201000008482 osteoarthritis Diseases 0.000 claims description 5
- LDCYZAJDBXYCGN-UHFFFAOYSA-N oxitriptan Natural products C1=C(O)C=C2C(CC(N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-UHFFFAOYSA-N 0.000 claims description 5
- 230000004584 weight gain Effects 0.000 claims description 5
- 235000019786 weight gain Nutrition 0.000 claims description 5
- 101150037123 APOE gene Proteins 0.000 claims description 4
- 206010034912 Phobia Diseases 0.000 claims description 4
- 229910052804 chromium Inorganic materials 0.000 claims description 4
- 239000011651 chromium Substances 0.000 claims description 4
- 150000001845 chromium compounds Chemical class 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 4
- 208000019899 phobic disease Diseases 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 101150072276 Gabrb3 gene Proteins 0.000 claims description 3
- 101000745167 Homo sapiens Neuronal acetylcholine receptor subunit alpha-4 Proteins 0.000 claims description 3
- 206010020400 Hostility Diseases 0.000 claims description 3
- 101150051213 MAOA gene Proteins 0.000 claims description 3
- 102100039909 Neuronal acetylcholine receptor subunit alpha-4 Human genes 0.000 claims description 3
- 206010029897 Obsessive thoughts Diseases 0.000 claims description 3
- 238000003935 denaturing gradient gel electrophoresis Methods 0.000 claims description 3
- 235000005686 eating Nutrition 0.000 claims description 3
- 210000003917 human chromosome Anatomy 0.000 claims description 3
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims description 3
- 239000003401 opiate antagonist Substances 0.000 claims description 3
- IFGCUJZIWBUILZ-UHFFFAOYSA-N sodium 2-[[2-[[hydroxy-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyphosphoryl]amino]-4-methylpentanoyl]amino]-3-(1H-indol-3-yl)propanoic acid Chemical compound [Na+].C=1NC2=CC=CC=C2C=1CC(C(O)=O)NC(=O)C(CC(C)C)NP(O)(=O)OC1OC(C)C(O)C(O)C1O IFGCUJZIWBUILZ-UHFFFAOYSA-N 0.000 claims description 3
- 201000006152 substance dependence Diseases 0.000 claims description 3
- 101150014463 ADRA2A gene Proteins 0.000 claims description 2
- 101150035834 GABRA3 gene Proteins 0.000 claims description 2
- 206010029216 Nervousness Diseases 0.000 claims description 2
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 101100244562 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) oprD gene Proteins 0.000 claims description 2
- 101150052737 adra2c gene Proteins 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- 230000021615 conjugation Effects 0.000 claims description 2
- 108700023159 delta Opioid Receptors Proteins 0.000 claims description 2
- 108010002591 epsilon receptor Proteins 0.000 claims description 2
- 239000003887 narcotic antagonist Substances 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- NGVDGCNFYWLIFO-UHFFFAOYSA-N pyridoxal 5'-phosphate Chemical compound CC1=NC=C(COP(O)(O)=O)C(C=O)=C1O NGVDGCNFYWLIFO-UHFFFAOYSA-N 0.000 claims description 2
- 235000007682 pyridoxal 5'-phosphate Nutrition 0.000 claims description 2
- 239000011589 pyridoxal 5'-phosphate Substances 0.000 claims description 2
- 230000000698 schizophrenic effect Effects 0.000 claims description 2
- 108020001612 μ-opioid receptors Proteins 0.000 claims description 2
- 102100020756 D(2) dopamine receptor Human genes 0.000 claims 15
- 101000931901 Homo sapiens D(2) dopamine receptor Proteins 0.000 claims 12
- 102000017904 ADRA2C Human genes 0.000 claims 10
- 102100040999 Catechol O-methyltransferase Human genes 0.000 claims 10
- 101000720032 Homo sapiens Alpha-2C adrenergic receptor Proteins 0.000 claims 10
- 101000694718 Homo sapiens Amine oxidase [flavin-containing] A Proteins 0.000 claims 10
- 101000892398 Homo sapiens Tryptophan 2,3-dioxygenase Proteins 0.000 claims 10
- 102100040653 Tryptophan 2,3-dioxygenase Human genes 0.000 claims 10
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 claims 9
- 101001003569 Homo sapiens LIM domain only protein 3 Proteins 0.000 claims 9
- 101001116937 Homo sapiens Protocadherin alpha-4 Proteins 0.000 claims 9
- 101000639972 Homo sapiens Sodium-dependent dopamine transporter Proteins 0.000 claims 9
- 102100026460 LIM domain only protein 3 Human genes 0.000 claims 9
- 102000017906 ADRA2A Human genes 0.000 claims 8
- 101000756842 Homo sapiens Alpha-2A adrenergic receptor Proteins 0.000 claims 7
- 206010014476 Elevated cholesterol Diseases 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims 2
- 230000000378 dietary effect Effects 0.000 claims 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims 2
- 239000011707 mineral Substances 0.000 claims 2
- BSKHPKMHTQYZBB-UHFFFAOYSA-N 2-methylpyridine Chemical compound CC1=CC=CC=N1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 claims 1
- 102100027493 5-hydroxytryptamine receptor 1D Human genes 0.000 claims 1
- 241000238876 Acari Species 0.000 claims 1
- 101150106671 COMT gene Proteins 0.000 claims 1
- 101000724739 Homo sapiens 5-hydroxytryptamine receptor 1D Proteins 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 206010022998 Irritability Diseases 0.000 claims 1
- 208000020358 Learning disease Diseases 0.000 claims 1
- 101001024425 Mus musculus Ig gamma-2A chain C region secreted form Proteins 0.000 claims 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims 1
- 125000003158 alcohol group Chemical group 0.000 claims 1
- 229940124277 aminobutyric acid Drugs 0.000 claims 1
- 230000009610 hypersensitivity Effects 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 229960003581 pyridoxal Drugs 0.000 claims 1
- 235000008164 pyridoxal Nutrition 0.000 claims 1
- 239000011674 pyridoxal Substances 0.000 claims 1
- 108010085082 sigma receptors Proteins 0.000 claims 1
- 230000000392 somatic effect Effects 0.000 claims 1
- 108020001588 κ-opioid receptors Proteins 0.000 claims 1
- 210000004556 brain Anatomy 0.000 abstract description 34
- 210000001009 nucleus accumben Anatomy 0.000 abstract description 18
- COLNVLDHVKWLRT-MRVPVSSYSA-N D-phenylalanine Chemical compound OC(=O)[C@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-MRVPVSSYSA-N 0.000 abstract description 13
- 229930182832 D-phenylalanine Natural products 0.000 abstract description 13
- 239000002792 enkephalinase inhibitor Substances 0.000 abstract description 7
- 239000003112 inhibitor Substances 0.000 abstract description 7
- 238000012545 processing Methods 0.000 abstract description 7
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract description 5
- 229960005190 phenylalanine Drugs 0.000 abstract description 5
- 229940122586 Enkephalinase inhibitor Drugs 0.000 abstract description 4
- 150000001844 chromium Chemical class 0.000 abstract description 4
- 235000001968 nicotinic acid Nutrition 0.000 abstract description 4
- 239000011664 nicotinic acid Substances 0.000 abstract description 4
- 229960004441 tyrosine Drugs 0.000 abstract description 4
- SIOXPEMLGUPBBT-UHFFFAOYSA-M picolinate Chemical compound [O-]C(=O)C1=CC=CC=N1 SIOXPEMLGUPBBT-UHFFFAOYSA-M 0.000 abstract description 3
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 abstract 1
- ZQPQGKQTIZYFEF-WCVJEAGWSA-N Huperzine Natural products C1([C@H]2[C@H](O)C(=O)N[C@H]2[C@@H](O)C=2C=CC=CC=2)=CC=CC=C1 ZQPQGKQTIZYFEF-WCVJEAGWSA-N 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 239000000544 cholinesterase inhibitor Substances 0.000 abstract 1
- 230000002363 herbicidal effect Effects 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 74
- 239000000523 sample Substances 0.000 description 66
- 108020004414 DNA Proteins 0.000 description 57
- 235000019441 ethanol Nutrition 0.000 description 54
- 230000003291 dopaminomimetic effect Effects 0.000 description 49
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 42
- 238000012360 testing method Methods 0.000 description 42
- 229960002748 norepinephrine Drugs 0.000 description 41
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 41
- 238000003199 nucleic acid amplification method Methods 0.000 description 39
- 230000003321 amplification Effects 0.000 description 38
- 102100033928 Sodium-dependent dopamine transporter Human genes 0.000 description 37
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 36
- 108020003175 receptors Proteins 0.000 description 36
- 229960003920 cocaine Drugs 0.000 description 35
- 238000005516 engineering process Methods 0.000 description 35
- 150000007523 nucleic acids Chemical group 0.000 description 35
- 238000001514 detection method Methods 0.000 description 31
- 230000002068 genetic effect Effects 0.000 description 31
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 27
- 102000039446 nucleic acids Human genes 0.000 description 27
- 108020004707 nucleic acids Proteins 0.000 description 27
- 102000005962 receptors Human genes 0.000 description 26
- 230000002829 reductive effect Effects 0.000 description 26
- 239000000047 product Substances 0.000 description 25
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 24
- 235000001014 amino acid Nutrition 0.000 description 24
- 238000004458 analytical method Methods 0.000 description 24
- 230000007423 decrease Effects 0.000 description 24
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 24
- 229960002715 nicotine Drugs 0.000 description 24
- 239000003550 marker Substances 0.000 description 23
- 230000009471 action Effects 0.000 description 22
- 238000009396 hybridization Methods 0.000 description 22
- 230000035772 mutation Effects 0.000 description 22
- 238000004166 bioassay Methods 0.000 description 21
- 102000004190 Enzymes Human genes 0.000 description 20
- 108090000790 Enzymes Proteins 0.000 description 20
- 230000000996 additive effect Effects 0.000 description 20
- 230000000295 complement effect Effects 0.000 description 20
- 201000010099 disease Diseases 0.000 description 20
- 229940088598 enzyme Drugs 0.000 description 20
- 230000003935 attention Effects 0.000 description 19
- 206010012335 Dependence Diseases 0.000 description 18
- 206010013654 Drug abuse Diseases 0.000 description 18
- 108050007331 Cannabinoid receptor Proteins 0.000 description 17
- 241000282412 Homo Species 0.000 description 17
- 210000002569 neuron Anatomy 0.000 description 17
- 239000000654 additive Substances 0.000 description 16
- 102000010909 Monoamine Oxidase Human genes 0.000 description 15
- 230000004060 metabolic process Effects 0.000 description 15
- 239000002773 nucleotide Substances 0.000 description 15
- 125000003729 nucleotide group Chemical group 0.000 description 15
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 14
- 108010092674 Enkephalins Proteins 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 14
- 238000003776 cleavage reaction Methods 0.000 description 14
- 239000000380 hallucinogen Substances 0.000 description 14
- QRMZSPFSDQBLIX-UHFFFAOYSA-N homovanillic acid Chemical compound COC1=CC(CC(O)=O)=CC=C1O QRMZSPFSDQBLIX-UHFFFAOYSA-N 0.000 description 14
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 13
- 102000053602 DNA Human genes 0.000 description 13
- 241000282414 Homo sapiens Species 0.000 description 13
- 102000057288 Tryptophan 2,3-dioxygenases Human genes 0.000 description 13
- 229940025084 amphetamine Drugs 0.000 description 13
- 230000007613 environmental effect Effects 0.000 description 13
- 230000008569 process Effects 0.000 description 13
- 208000020016 psychiatric disease Diseases 0.000 description 13
- 230000007017 scission Effects 0.000 description 13
- 102000006378 Catechol O-methyltransferase Human genes 0.000 description 12
- 230000006870 function Effects 0.000 description 12
- 238000011160 research Methods 0.000 description 12
- 230000035882 stress Effects 0.000 description 12
- 208000005374 Poisoning Diseases 0.000 description 11
- 241000700159 Rattus Species 0.000 description 11
- 239000000556 agonist Substances 0.000 description 11
- 238000013459 approach Methods 0.000 description 11
- 150000001720 carbohydrates Chemical class 0.000 description 11
- 235000014633 carbohydrates Nutrition 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 11
- 230000001419 dependent effect Effects 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 231100000572 poisoning Toxicity 0.000 description 11
- 230000000607 poisoning effect Effects 0.000 description 11
- 206010012218 Delirium Diseases 0.000 description 10
- 108010093625 Opioid Peptides Proteins 0.000 description 10
- 102000001490 Opioid Peptides Human genes 0.000 description 10
- 108010083644 Ribonucleases Proteins 0.000 description 10
- 102000006382 Ribonucleases Human genes 0.000 description 10
- 230000003993 interaction Effects 0.000 description 10
- 208000020925 Bipolar disease Diseases 0.000 description 9
- 108010044266 Dopamine Plasma Membrane Transport Proteins Proteins 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 240000004308 marijuana Species 0.000 description 9
- 239000003399 opiate peptide Substances 0.000 description 9
- 210000002381 plasma Anatomy 0.000 description 9
- 230000009467 reduction Effects 0.000 description 9
- FBWPWWWZWKPJFL-UHFFFAOYSA-N 3-Methoxy-4-hydroxyphenylethyleneglycol Chemical compound COC1=CC(C(O)CO)=CC=C1O FBWPWWWZWKPJFL-UHFFFAOYSA-N 0.000 description 8
- 208000028698 Cognitive impairment Diseases 0.000 description 8
- 108090001111 Dopamine D2 Receptors Proteins 0.000 description 8
- 208000004547 Hallucinations Diseases 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 8
- 230000005856 abnormality Effects 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 8
- 239000000969 carrier Substances 0.000 description 8
- 230000001684 chronic effect Effects 0.000 description 8
- 208000010877 cognitive disease Diseases 0.000 description 8
- 230000006735 deficit Effects 0.000 description 8
- 230000007717 exclusion Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 8
- 230000007246 mechanism Effects 0.000 description 8
- 108020004999 messenger RNA Proteins 0.000 description 8
- 229930182837 (R)-adrenaline Natural products 0.000 description 7
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 7
- 206010012239 Delusion Diseases 0.000 description 7
- 108700024394 Exon Proteins 0.000 description 7
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 7
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 7
- 239000005557 antagonist Substances 0.000 description 7
- 229960002802 bromocriptine Drugs 0.000 description 7
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 description 7
- 230000008859 change Effects 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 231100000868 delusion Toxicity 0.000 description 7
- 229960005139 epinephrine Drugs 0.000 description 7
- 230000000971 hippocampal effect Effects 0.000 description 7
- 230000033001 locomotion Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 208000022821 personality disease Diseases 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 230000001105 regulatory effect Effects 0.000 description 7
- 230000003936 working memory Effects 0.000 description 7
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 6
- 102000004980 Dopamine D2 Receptors Human genes 0.000 description 6
- 108010015720 Dopamine beta-Hydroxylase Proteins 0.000 description 6
- 108050004812 Dopamine receptor Proteins 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 6
- 208000019022 Mood disease Diseases 0.000 description 6
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 6
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 6
- 210000000577 adipose tissue Anatomy 0.000 description 6
- 210000004227 basal ganglia Anatomy 0.000 description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 6
- 230000017531 blood circulation Effects 0.000 description 6
- 150000003943 catecholamines Chemical class 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000007547 defect Effects 0.000 description 6
- 239000000499 gel Substances 0.000 description 6
- 238000003205 genotyping method Methods 0.000 description 6
- 239000008103 glucose Substances 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 6
- 210000001320 hippocampus Anatomy 0.000 description 6
- 230000036651 mood Effects 0.000 description 6
- 210000001577 neostriatum Anatomy 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 208000020685 sleep-wake disease Diseases 0.000 description 6
- 230000002123 temporal effect Effects 0.000 description 6
- 208000016686 tic disease Diseases 0.000 description 6
- 208000016261 weight loss Diseases 0.000 description 6
- 230000004580 weight loss Effects 0.000 description 6
- 206010000117 Abnormal behaviour Diseases 0.000 description 5
- 206010001488 Aggression Diseases 0.000 description 5
- 108010078791 Carrier Proteins Proteins 0.000 description 5
- 241000282693 Cercopithecidae Species 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 5
- 208000026350 Inborn Genetic disease Diseases 0.000 description 5
- 108010007622 LDL Lipoproteins Proteins 0.000 description 5
- 102000007330 LDL Lipoproteins Human genes 0.000 description 5
- 102000016267 Leptin Human genes 0.000 description 5
- 108010092277 Leptin Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 5
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 description 5
- 102000004279 Oxytocin receptors Human genes 0.000 description 5
- 108090000876 Oxytocin receptors Proteins 0.000 description 5
- 201000001880 Sexual dysfunction Diseases 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 208000028683 bipolar I disease Diseases 0.000 description 5
- 230000036772 blood pressure Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 5
- 230000003920 cognitive function Effects 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000008451 emotion Effects 0.000 description 5
- 229960004756 ethanol Drugs 0.000 description 5
- 230000003371 gabaergic effect Effects 0.000 description 5
- 208000016361 genetic disease Diseases 0.000 description 5
- 208000013403 hyperactivity Diseases 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 5
- 229940039781 leptin Drugs 0.000 description 5
- 230000001404 mediated effect Effects 0.000 description 5
- 229960001344 methylphenidate Drugs 0.000 description 5
- 208000019906 panic disease Diseases 0.000 description 5
- 238000007894 restriction fragment length polymorphism technique Methods 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 231100000872 sexual dysfunction Toxicity 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 238000012549 training Methods 0.000 description 5
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
- 208000029197 Amphetamine-Related disease Diseases 0.000 description 4
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 4
- 102000015554 Dopamine receptor Human genes 0.000 description 4
- 101150068427 EP300 gene Proteins 0.000 description 4
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
- 102100038885 Histone acetyltransferase p300 Human genes 0.000 description 4
- 102000004877 Insulin Human genes 0.000 description 4
- 108090001061 Insulin Proteins 0.000 description 4
- 208000003863 Marijuana Abuse Diseases 0.000 description 4
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 4
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 4
- 206010057852 Nicotine dependence Diseases 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 208000026251 Opioid-Related disease Diseases 0.000 description 4
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 4
- 206010036618 Premenstrual syndrome Diseases 0.000 description 4
- 108020004518 RNA Probes Proteins 0.000 description 4
- 239000003391 RNA probe Substances 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000025569 Tobacco Use disease Diseases 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 208000012761 aggressive behavior Diseases 0.000 description 4
- 208000029650 alcohol withdrawal Diseases 0.000 description 4
- 230000004075 alteration Effects 0.000 description 4
- 230000005540 biological transmission Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 230000003925 brain function Effects 0.000 description 4
- 229930003827 cannabinoid Natural products 0.000 description 4
- 239000003557 cannabinoid Substances 0.000 description 4
- 229940077731 carbohydrate nutrients Drugs 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000001713 cholinergic effect Effects 0.000 description 4
- 201000001272 cocaine abuse Diseases 0.000 description 4
- 208000012696 congenital leptin deficiency Diseases 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 235000019788 craving Nutrition 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 230000008482 dysregulation Effects 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 210000001652 frontal lobe Anatomy 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940125396 insulin Drugs 0.000 description 4
- IMYZQPCYWPFTAG-IQJOONFLSA-N mecamylamine Chemical compound C1C[C@@H]2C(C)(C)[C@@](NC)(C)[C@H]1C2 IMYZQPCYWPFTAG-IQJOONFLSA-N 0.000 description 4
- 229960002525 mecamylamine Drugs 0.000 description 4
- 210000001259 mesencephalon Anatomy 0.000 description 4
- 208000001022 morbid obesity Diseases 0.000 description 4
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 230000001722 neurochemical effect Effects 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 230000002085 persistent effect Effects 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 210000002442 prefrontal cortex Anatomy 0.000 description 4
- 239000000018 receptor agonist Substances 0.000 description 4
- 229940044601 receptor agonist Drugs 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 238000000611 regression analysis Methods 0.000 description 4
- 108091008146 restriction endonucleases Proteins 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 235000019615 sensations Nutrition 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000001568 sexual effect Effects 0.000 description 4
- 239000000021 stimulant Substances 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 230000009469 supplementation Effects 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
- 108010078554 Aromatase Proteins 0.000 description 3
- 206010006550 Bulimia nervosa Diseases 0.000 description 3
- 102100029136 Collagen alpha-1(II) chain Human genes 0.000 description 3
- 150000008574 D-amino acids Chemical class 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 3
- 208000030814 Eating disease Diseases 0.000 description 3
- 240000006890 Erythroxylum coca Species 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 208000019454 Feeding and Eating disease Diseases 0.000 description 3
- 206010071602 Genetic polymorphism Diseases 0.000 description 3
- 101000771163 Homo sapiens Collagen alpha-1(II) chain Proteins 0.000 description 3
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 3
- 108091092919 Minisatellite Proteins 0.000 description 3
- 101710112393 Mitochondrial uncoupling protein 2 Proteins 0.000 description 3
- 102100040200 Mitochondrial uncoupling protein 2 Human genes 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102000003840 Opioid Receptors Human genes 0.000 description 3
- 108090000137 Opioid Receptors Proteins 0.000 description 3
- 206010033307 Overweight Diseases 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 108020004682 Single-Stranded DNA Proteins 0.000 description 3
- 206010043903 Tobacco abuse Diseases 0.000 description 3
- JXNRXNCCROJZFB-RYUDHWBXSA-N Tyr-Arg Chemical compound NC(=N)NCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-RYUDHWBXSA-N 0.000 description 3
- 108091027569 Z-DNA Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 238000007792 addition Methods 0.000 description 3
- 230000002730 additional effect Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 229960002685 biotin Drugs 0.000 description 3
- 235000020958 biotin Nutrition 0.000 description 3
- 239000011616 biotin Substances 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 210000003169 central nervous system Anatomy 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 235000008957 cocaer Nutrition 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000002405 diagnostic procedure Methods 0.000 description 3
- 235000014632 disordered eating Nutrition 0.000 description 3
- 230000010249 dopaminergic function Effects 0.000 description 3
- 230000004064 dysfunction Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 230000004153 glucose metabolism Effects 0.000 description 3
- 229960003878 haloperidol Drugs 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 108010053037 kyotorphin Proteins 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 230000002197 limbic effect Effects 0.000 description 3
- 238000011068 loading method Methods 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 230000002474 noradrenergic effect Effects 0.000 description 3
- 210000004940 nucleus Anatomy 0.000 description 3
- 235000020825 overweight Nutrition 0.000 description 3
- 229910052698 phosphorus Inorganic materials 0.000 description 3
- 239000011574 phosphorus Substances 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 229920002401 polyacrylamide Polymers 0.000 description 3
- 208000028280 polygenic inheritance Diseases 0.000 description 3
- 230000002360 prefrontal effect Effects 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 230000001107 psychogenic effect Effects 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 230000000862 serotonergic effect Effects 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000003478 temporal lobe Anatomy 0.000 description 3
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000012800 visualization Methods 0.000 description 3
- FGHVSEXHEAUJBT-HFNHQGOYSA-N (z)-but-2-enedioic acid;(5r)-8-chloro-3-methyl-5-phenyl-1,2,4,5-tetrahydro-3-benzazepin-7-ol Chemical compound OC(=O)\C=C/C(O)=O.C1([C@@H]2C3=CC(O)=C(Cl)C=C3CCN(C2)C)=CC=CC=C1 FGHVSEXHEAUJBT-HFNHQGOYSA-N 0.000 description 2
- WAOQONBSWFLFPE-VIFPVBQESA-N 3,5-dichloro-N-[[(2S)-1-ethyl-2-pyrrolidinyl]methyl]-2-hydroxy-6-methoxybenzamide Chemical compound CCN1CCC[C@H]1CNC(=O)C1=C(O)C(Cl)=CC(Cl)=C1OC WAOQONBSWFLFPE-VIFPVBQESA-N 0.000 description 2
- NPILLHMQNMXXTL-UHFFFAOYSA-N 4,4'-dimethylaminorex Chemical compound CC1N=C(N)OC1C1=CC=C(C)C=C1 NPILLHMQNMXXTL-UHFFFAOYSA-N 0.000 description 2
- 208000017194 Affective disease Diseases 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- 102100028116 Amine oxidase [flavin-containing] B Human genes 0.000 description 2
- 102000014654 Aromatase Human genes 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 108020004705 Codon Proteins 0.000 description 2
- 102100040512 Collagen alpha-1(IX) chain Human genes 0.000 description 2
- ROHFNLRQFUQHCH-RXMQYKEDSA-N D-leucine Chemical compound CC(C)C[C@@H](N)C(O)=O ROHFNLRQFUQHCH-RXMQYKEDSA-N 0.000 description 2
- 208000026331 Disruptive, Impulse Control, and Conduct disease Diseases 0.000 description 2
- 101150097070 Drd3 gene Proteins 0.000 description 2
- 206010013752 Drug withdrawal convulsions Diseases 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 206010015535 Euphoric mood Diseases 0.000 description 2
- 101150007028 HTRA1 gene Proteins 0.000 description 2
- GVGLGOZIDCSQPN-PVHGPHFFSA-N Heroin Chemical compound O([C@H]1[C@H](C=C[C@H]23)OC(C)=O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4OC(C)=O GVGLGOZIDCSQPN-PVHGPHFFSA-N 0.000 description 2
- 101000768078 Homo sapiens Amine oxidase [flavin-containing] B Proteins 0.000 description 2
- 101000749901 Homo sapiens Collagen alpha-1(IX) chain Proteins 0.000 description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- 101001063991 Homo sapiens Leptin Proteins 0.000 description 2
- 206010020710 Hyperphagia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- 239000004395 L-leucine Substances 0.000 description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 2
- 102000003960 Ligases Human genes 0.000 description 2
- 108090000364 Ligases Proteins 0.000 description 2
- 101150115032 MAOB gene Proteins 0.000 description 2
- 102100039364 Metalloproteinase inhibitor 1 Human genes 0.000 description 2
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 2
- 108050002686 Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 2
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 2
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 2
- 240000007594 Oryza sativa Species 0.000 description 2
- 235000007164 Oryza sativa Nutrition 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 101150093308 POMC gene Proteins 0.000 description 2
- 208000006199 Parasomnias Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 108010069820 Pro-Opiomelanocortin Proteins 0.000 description 2
- 239000000683 Pro-Opiomelanocortin Substances 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 241000220317 Rosa Species 0.000 description 2
- 102100021119 Serine protease HTRA1 Human genes 0.000 description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 208000013200 Stress disease Diseases 0.000 description 2
- 208000017413 Taqi polymorphism Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 108091036066 Three prime untranslated region Proteins 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000004404 adrenal cortex Anatomy 0.000 description 2
- UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
- 208000028505 alcohol-related disease Diseases 0.000 description 2
- 230000036626 alertness Effects 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 108020004101 alpha-2 Adrenergic Receptor Proteins 0.000 description 2
- 102000030484 alpha-2 Adrenergic Receptor Human genes 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 230000003097 anti-respiratory effect Effects 0.000 description 2
- 208000024823 antisocial personality disease Diseases 0.000 description 2
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 2
- 230000037007 arousal Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 201000001843 cannabis dependence Diseases 0.000 description 2
- 108091092328 cellular RNA Proteins 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003710 cerebral cortex Anatomy 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 229960002896 clonidine Drugs 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 230000007278 cognition impairment Effects 0.000 description 2
- 230000001149 cognitive effect Effects 0.000 description 2
- 231100000867 compulsive behavior Toxicity 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000001784 detoxification Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229960002069 diamorphine Drugs 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- 239000003210 dopamine receptor blocking agent Substances 0.000 description 2
- 230000028436 dopamine uptake Effects 0.000 description 2
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 2
- 206010013932 dyslexia Diseases 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 230000000706 effect on dopamine Effects 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 210000005153 frontal cortex Anatomy 0.000 description 2
- 101150034785 gamma gene Proteins 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 102000034356 gene-regulatory proteins Human genes 0.000 description 2
- 108091006104 gene-regulatory proteins Proteins 0.000 description 2
- 230000009395 genetic defect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 206010020765 hypersomnia Diseases 0.000 description 2
- 230000003116 impacting effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010022437 insomnia Diseases 0.000 description 2
- 208000015046 intermittent explosive disease Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000000622 irritating effect Effects 0.000 description 2
- 238000011901 isothermal amplification Methods 0.000 description 2
- 230000008449 language Effects 0.000 description 2
- 108010019813 leptin receptors Proteins 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- 238000011694 lewis rat Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 210000003715 limbic system Anatomy 0.000 description 2
- 206010025135 lupus erythematosus Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000006386 memory function Effects 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 2
- 229960001252 methamphetamine Drugs 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- 210000000118 neural pathway Anatomy 0.000 description 2
- 230000010004 neural pathway Effects 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000000422 nocturnal effect Effects 0.000 description 2
- 239000002853 nucleic acid probe Substances 0.000 description 2
- 235000020830 overeating Nutrition 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- DHHVAGZRUROJKS-UHFFFAOYSA-N phentermine Chemical compound CC(C)(N)CC1=CC=CC=C1 DHHVAGZRUROJKS-UHFFFAOYSA-N 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000003518 presynaptic effect Effects 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- RXWNCPJZOCPEPQ-NVWDDTSBSA-N puromycin Chemical compound C1=CC(OC)=CC=C1C[C@H](N)C(=O)N[C@H]1[C@@H](O)[C@H](N2C3=NC=NC(=C3N=C2)N(C)C)O[C@@H]1CO RXWNCPJZOCPEPQ-NVWDDTSBSA-N 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 229950001518 raclopride Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 230000003252 repetitive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 235000009566 rice Nutrition 0.000 description 2
- 102220191945 rs200073359 Human genes 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000013517 stratification Methods 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 210000000225 synapse Anatomy 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000012384 transportation and delivery Methods 0.000 description 2
- 230000001960 triggered effect Effects 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 210000004515 ventral tegmental area Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 230000001755 vocal effect Effects 0.000 description 2
- YFGBQHOOROIVKG-BHDDXSALSA-N (2R)-2-[[(2R)-2-[[2-[[2-[[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]acetyl]amino]-3-phenylpropanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound C([C@H](C(=O)N[C@H](CCSC)C(O)=O)NC(=O)CNC(=O)CNC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 YFGBQHOOROIVKG-BHDDXSALSA-N 0.000 description 1
- PYHRZPFZZDCOPH-QXGOIDDHSA-N (S)-amphetamine sulfate Chemical compound [H+].[H+].[O-]S([O-])(=O)=O.C[C@H](N)CC1=CC=CC=C1.C[C@H](N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-QXGOIDDHSA-N 0.000 description 1
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 108020005345 3' Untranslated Regions Proteins 0.000 description 1
- IRJNJBIOUYJBHG-UHFFFAOYSA-N 3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound CN1CCCC1C1=CC=CN=C1.CN1CCCC1C1=CC=CN=C1 IRJNJBIOUYJBHG-UHFFFAOYSA-N 0.000 description 1
- 108091005479 5-HT2 receptors Proteins 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- HFDKKNHCYWNNNQ-YOGANYHLSA-N 75976-10-2 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)N)C(C)C)[C@@H](C)O)C1=CC=C(O)C=C1 HFDKKNHCYWNNNQ-YOGANYHLSA-N 0.000 description 1
- ZKRFOXLVOKTUTA-KQYNXXCUSA-N 9-(5-phosphoribofuranosyl)-6-mercaptopurine Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=S)=C2N=C1 ZKRFOXLVOKTUTA-KQYNXXCUSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 102100030913 Acetylcholine receptor subunit alpha Human genes 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102100036601 Aggrecan core protein Human genes 0.000 description 1
- 241001514645 Agonis Species 0.000 description 1
- 208000008811 Agoraphobia Diseases 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000031091 Amnestic disease Diseases 0.000 description 1
- 102100032187 Androgen receptor Human genes 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 102000009333 Apolipoprotein D Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 108010025614 Apolipoproteins D Proteins 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000027448 Attention Deficit and Disruptive Behavior disease Diseases 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010001478 Bacitracin Proteins 0.000 description 1
- 241000616862 Belliella Species 0.000 description 1
- 208000008882 Benign Neonatal Epilepsy Diseases 0.000 description 1
- 206010067866 Benign familial neonatal convulsions Diseases 0.000 description 1
- VGGGPCQERPFHOB-MCIONIFRSA-N Bestatin Chemical compound CC(C)C[C@H](C(O)=O)NC(=O)[C@@H](O)[C@H](N)CC1=CC=CC=C1 VGGGPCQERPFHOB-MCIONIFRSA-N 0.000 description 1
- VGGGPCQERPFHOB-UHFFFAOYSA-N Bestatin Natural products CC(C)CC(C(O)=O)NC(=O)C(O)C(N)CC1=CC=CC=C1 VGGGPCQERPFHOB-UHFFFAOYSA-N 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 description 1
- 208000032841 Bulimia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 102100037182 Cation-independent mannose-6-phosphate receptor Human genes 0.000 description 1
- 230000010779 Cholinergic Interactions Effects 0.000 description 1
- 102000009660 Cholinergic Receptors Human genes 0.000 description 1
- 108010009685 Cholinergic Receptors Proteins 0.000 description 1
- 206010008674 Cholinergic syndrome Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 238000006066 Comins reaction Methods 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- 229930182819 D-leucine Natural products 0.000 description 1
- 101150037021 D2 gene Proteins 0.000 description 1
- 101150090600 D3 gene Proteins 0.000 description 1
- 101150032009 D4 gene Proteins 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 238000000018 DNA microarray Methods 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000004568 DNA-binding Effects 0.000 description 1
- 241000965476 Darksidea beta Species 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- JXNRXNCCROJZFB-UHFFFAOYSA-N Di-Me ester-(2R, 3E)-Phytochromobilin Natural products NC(N)=NCCCC(C(O)=O)NC(=O)C(N)CC1=CC=C(O)C=C1 JXNRXNCCROJZFB-UHFFFAOYSA-N 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 206010013486 Distractibility Diseases 0.000 description 1
- 102100039104 Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Human genes 0.000 description 1
- 108090000357 Dopamine D4 receptors Proteins 0.000 description 1
- 101150091394 Drd5 gene Proteins 0.000 description 1
- 101100228149 Drosophila melanogaster Trl gene Proteins 0.000 description 1
- 208000003870 Drug Overdose Diseases 0.000 description 1
- 101800003122 ENk Proteins 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 241001125671 Eretmochelys imbricata Species 0.000 description 1
- 241001539473 Euphoria Species 0.000 description 1
- 206010070246 Executive dysfunction Diseases 0.000 description 1
- 208000001836 Firesetting Behavior Diseases 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- 102100029974 GTPase HRas Human genes 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 101000726895 Homo sapiens Acetylcholine receptor subunit alpha Proteins 0.000 description 1
- 101001028831 Homo sapiens Cation-independent mannose-6-phosphate receptor Proteins 0.000 description 1
- 101000884921 Homo sapiens Dolichyl-diphosphooligosaccharide-protein glycosyltransferase subunit DAD1 Proteins 0.000 description 1
- 101000584633 Homo sapiens GTPase HRas Proteins 0.000 description 1
- 101000893424 Homo sapiens Glucokinase regulatory protein Proteins 0.000 description 1
- 101001076310 Homo sapiens Insulin growth factor-like family member 1 Proteins 0.000 description 1
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
- 101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
- 101001002634 Homo sapiens Interleukin-1 alpha Proteins 0.000 description 1
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101001076418 Homo sapiens Interleukin-1 receptor type 1 Proteins 0.000 description 1
- 101000990902 Homo sapiens Matrix metalloproteinase-9 Proteins 0.000 description 1
- 101000669513 Homo sapiens Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 101001059982 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 5 Proteins 0.000 description 1
- 101000828537 Homo sapiens Synaptic functional regulator FMR1 Proteins 0.000 description 1
- 101100480415 Homo sapiens TDO2 gene Proteins 0.000 description 1
- 101000635938 Homo sapiens Transforming growth factor beta-1 proprotein Proteins 0.000 description 1
- 101000635958 Homo sapiens Transforming growth factor beta-2 proprotein Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 101000829171 Hypocrea virens (strain Gv29-8 / FGSC 10586) Effector TSP1 Proteins 0.000 description 1
- 206010071081 Idiopathic generalised epilepsy Diseases 0.000 description 1
- 208000016588 Idiopathic hypersomnia Diseases 0.000 description 1
- 102100023915 Insulin Human genes 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 102100025964 Insulin growth factor-like family member 1 Human genes 0.000 description 1
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 1
- 102100025947 Insulin-like growth factor II Human genes 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 102100039065 Interleukin-1 beta Human genes 0.000 description 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 1
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 101150068332 KIT gene Proteins 0.000 description 1
- 208000027747 Kennedy disease Diseases 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 1
- 208000024556 Mendelian disease Diseases 0.000 description 1
- 102400000988 Met-enkephalin Human genes 0.000 description 1
- 108050006599 Metalloproteinase inhibitor 1 Proteins 0.000 description 1
- 108010042237 Methionine Enkephalin Proteins 0.000 description 1
- 102100028195 Mitogen-activated protein kinase kinase kinase kinase 5 Human genes 0.000 description 1
- 101100181592 Mus musculus Lep gene Proteins 0.000 description 1
- 102000010645 MutS Proteins Human genes 0.000 description 1
- 108010038272 MutS Proteins Proteins 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108050002826 Neuropeptide Y Receptor Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 208000000224 Night Terrors Diseases 0.000 description 1
- 206010029412 Nightmare Diseases 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 241000669618 Nothes Species 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 206010033296 Overdoses Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000018886 Pancreatic Polypeptide Human genes 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- 206010033668 Panic disorder without agoraphobia Diseases 0.000 description 1
- 241000935974 Paralichthys dentatus Species 0.000 description 1
- 206010033864 Paranoia Diseases 0.000 description 1
- 208000027099 Paranoid disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 108010002822 Phenylethanolamine N-Methyltransferase Proteins 0.000 description 1
- 102100028917 Phenylethanolamine N-methyltransferase Human genes 0.000 description 1
- 208000007222 Physiological Sexual Dysfunction Diseases 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 101150021841 Pnmt gene Proteins 0.000 description 1
- 206010062519 Poor quality sleep Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 229940123573 Protein synthesis inhibitor Drugs 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010037180 Psychiatric symptoms Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108010066717 Q beta Replicase Proteins 0.000 description 1
- 208000022372 Reading disease Diseases 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 108091006419 SLC25A12 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000028810 Shared psychotic disease Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 206010040981 Sleep attacks Diseases 0.000 description 1
- 208000035558 Sleep disorders due to general medical condition Diseases 0.000 description 1
- 206010041010 Sleep terror Diseases 0.000 description 1
- 206010041250 Social phobia Diseases 0.000 description 1
- 101710114615 Sodium-dependent dopamine transporter Proteins 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 206010041347 Somnambulism Diseases 0.000 description 1
- 206010042008 Stereotypy Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 101000983124 Sus scrofa Pancreatic prohormone precursor Proteins 0.000 description 1
- 102100023532 Synaptic functional regulator FMR1 Human genes 0.000 description 1
- 101710137500 T7 RNA polymerase Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 102100030742 Transforming growth factor beta-1 proprotein Human genes 0.000 description 1
- 102100030737 Transforming growth factor beta-2 proprotein Human genes 0.000 description 1
- 108091007498 Transmembrane domain 2 Proteins 0.000 description 1
- 208000031674 Traumatic Acute Stress disease Diseases 0.000 description 1
- 108091000117 Tyrosine 3-Monooxygenase Proteins 0.000 description 1
- 102000048218 Tyrosine 3-monooxygenases Human genes 0.000 description 1
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 1
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 1
- 108010046334 Urease Proteins 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 description 1
- 101150044453 Y gene Proteins 0.000 description 1
- DGEZNRSVGBDHLK-UHFFFAOYSA-N [1,10]phenanthroline Chemical compound C1=CN=C2C3=NC=CC=C3C=CC2=C1 DGEZNRSVGBDHLK-UHFFFAOYSA-N 0.000 description 1
- 238000003677 abuse test Methods 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 208000026345 acute stress disease Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 210000003486 adipose tissue brown Anatomy 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000001800 adrenalinergic effect Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000011717 all-trans-retinol Substances 0.000 description 1
- 235000019169 all-trans-retinol Nutrition 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- QXAITBQSYVNQDR-UHFFFAOYSA-N amitraz Chemical compound C=1C=C(C)C=C(C)C=1N=CN(C)C=NC1=CC=C(C)C=C1C QXAITBQSYVNQDR-UHFFFAOYSA-N 0.000 description 1
- 230000006986 amnesia Effects 0.000 description 1
- 201000002472 amphetamine abuse Diseases 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- 230000002547 anomalous effect Effects 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 208000021018 autosomal dominant inheritance Diseases 0.000 description 1
- 208000008233 autosomal dominant nocturnal frontal lobe epilepsy Diseases 0.000 description 1
- 229960003071 bacitracin Drugs 0.000 description 1
- 229930184125 bacitracin Natural products 0.000 description 1
- CLKOFPXJLQSYAH-ABRJDSQDSA-N bacitracin A Chemical compound C1SC([C@@H](N)[C@@H](C)CC)=N[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]1C(=O)N[C@H](CCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2N=CNC=2)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)NCCCC1 CLKOFPXJLQSYAH-ABRJDSQDSA-N 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 201000003452 benign familial neonatal epilepsy Diseases 0.000 description 1
- 201000010295 benign neonatal seizures Diseases 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000002902 bimodal effect Effects 0.000 description 1
- 230000000035 biogenic effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 208000022257 bipolar II disease Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 208000030963 borderline personality disease Diseases 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 230000010336 brain pathway Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- 210000004900 c-terminal fragment Anatomy 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 238000004422 calculation algorithm Methods 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 201000009322 cannabis abuse Diseases 0.000 description 1
- 235000021074 carbohydrate intake Nutrition 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000012412 chemical coupling Methods 0.000 description 1
- 238000000546 chi-square test Methods 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000006949 cholinergic function Effects 0.000 description 1
- 238000009142 chromium supplementation Methods 0.000 description 1
- 229910000151 chromium(III) phosphate Inorganic materials 0.000 description 1
- IKZBVTPSNGOVRJ-UHFFFAOYSA-K chromium(iii) phosphate Chemical compound [Cr+3].[O-]P([O-])([O-])=O IKZBVTPSNGOVRJ-UHFFFAOYSA-K 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 230000027288 circadian rhythm Effects 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 230000003930 cognitive ability Effects 0.000 description 1
- 230000003931 cognitive performance Effects 0.000 description 1
- 239000003283 colorimetric indicator Substances 0.000 description 1
- 230000001447 compensatory effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000006957 competitive inhibition Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007585 cortical function Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 101150012893 dat gene Proteins 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 102000048124 delta Opioid Receptors Human genes 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 210000001947 dentate gyrus Anatomy 0.000 description 1
- 239000007933 dermal patch Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000632 dexamfetamine Drugs 0.000 description 1
- 229940099242 dexedrine Drugs 0.000 description 1
- 101150024103 dhd gene Proteins 0.000 description 1
- 238000007435 diagnostic evaluation Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 235000008242 dietary patterns Nutrition 0.000 description 1
- 235000021004 dietary regimen Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- XPPKVPWEQAFLFU-UHFFFAOYSA-N diphosphoric acid Chemical compound OP(O)(=O)OP(O)(O)=O XPPKVPWEQAFLFU-UHFFFAOYSA-N 0.000 description 1
- BFMYDTVEBKDAKJ-UHFFFAOYSA-L disodium;(2',7'-dibromo-3',6'-dioxido-3-oxospiro[2-benzofuran-1,9'-xanthene]-4'-yl)mercury;hydrate Chemical compound O.[Na+].[Na+].O1C(=O)C2=CC=CC=C2C21C1=CC(Br)=C([O-])C([Hg])=C1OC1=C2C=C(Br)C([O-])=C1 BFMYDTVEBKDAKJ-UHFFFAOYSA-L 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000002804 dopamine agent Substances 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 231100000725 drug overdose Toxicity 0.000 description 1
- 201000002545 drug psychosis Diseases 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000020595 eating behavior Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- ZMMJGEGLRURXTF-UHFFFAOYSA-N ethidium bromide Chemical compound [Br-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CC)=C1C1=CC=CC=C1 ZMMJGEGLRURXTF-UHFFFAOYSA-N 0.000 description 1
- 229960005542 ethidium bromide Drugs 0.000 description 1
- 230000002743 euphoric effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004634 feeding behavior Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000019525 fullness Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 102000054767 gene variant Human genes 0.000 description 1
- 208000037870 generalized anxiety Diseases 0.000 description 1
- 230000004077 genetic alteration Effects 0.000 description 1
- 231100000118 genetic alteration Toxicity 0.000 description 1
- 238000012252 genetic analysis Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000008303 genetic mechanism Effects 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 230000007614 genetic variation Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 108010070004 glucose receptor Proteins 0.000 description 1
- 229960002743 glutamine Drugs 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 1
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical class O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 1
- 230000002650 habitual effect Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 201000002270 hallucinogen abuse Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000003505 heat denaturation Methods 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 102000049953 human LEP Human genes 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 201000001993 idiopathic generalized epilepsy Diseases 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000010365 information processing Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000008611 intercellular interaction Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004068 intracellular signaling Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 238000001698 laser desorption ionisation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000007834 ligase chain reaction Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000004904 long-term response Effects 0.000 description 1
- 230000027928 long-term synaptic potentiation Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000005171 mammalian brain Anatomy 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- JUMYIBMBTDDLNG-UHFFFAOYSA-N methylphenidate hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(C(=O)OC)C1CCCC[NH2+]1 JUMYIBMBTDDLNG-UHFFFAOYSA-N 0.000 description 1
- 238000001690 micro-dialysis Methods 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- JITOKQVGRJSHHA-UHFFFAOYSA-M monosodium methyl arsenate Chemical group [Na+].C[As](O)([O-])=O JITOKQVGRJSHHA-UHFFFAOYSA-M 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 239000000472 muscarinic agonist Substances 0.000 description 1
- 210000004898 n-terminal fragment Anatomy 0.000 description 1
- UZHSEJADLWPNLE-GRGSLBFTSA-N naloxone Chemical compound O=C([C@@H]1O2)CC[C@@]3(O)[C@H]4CC5=CC=C(O)C2=C5[C@@]13CCN4CC=C UZHSEJADLWPNLE-GRGSLBFTSA-N 0.000 description 1
- 229960004127 naloxone Drugs 0.000 description 1
- DQCKKXVULJGBQN-XFWGSAIBSA-N naltrexone Chemical compound N1([C@@H]2CC3=CC=C(C=4O[C@@H]5[C@](C3=4)([C@]2(CCC5=O)O)CC1)O)CC1CC1 DQCKKXVULJGBQN-XFWGSAIBSA-N 0.000 description 1
- 229960003086 naltrexone Drugs 0.000 description 1
- 230000003533 narcotic effect Effects 0.000 description 1
- 210000000478 neocortex Anatomy 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 238000002610 neuroimaging Methods 0.000 description 1
- 230000007658 neurological function Effects 0.000 description 1
- 230000003227 neuromodulating effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000000181 nicotinic agonist Substances 0.000 description 1
- 239000003367 nicotinic antagonist Substances 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000001668 nucleic acid synthesis Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 210000000869 occipital lobe Anatomy 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 201000005040 opiate dependence Diseases 0.000 description 1
- 201000000988 opioid abuse Diseases 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 230000000406 opioidergic effect Effects 0.000 description 1
- 230000002450 orbitofrontal effect Effects 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229940096717 pamine Drugs 0.000 description 1
- 210000001152 parietal lobe Anatomy 0.000 description 1
- 230000008775 paternal effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 238000011056 performance test Methods 0.000 description 1
- 229960004851 pergolide Drugs 0.000 description 1
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 229960003562 phentermine Drugs 0.000 description 1
- RGCLLPNLLBQHPF-HJWRWDBZSA-N phosphamidon Chemical compound CCN(CC)C(=O)C(\Cl)=C(/C)OP(=O)(OC)OC RGCLLPNLLBQHPF-HJWRWDBZSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 108010040003 polyglutamine Proteins 0.000 description 1
- 229920000155 polyglutamine Polymers 0.000 description 1
- 235000020004 porter Nutrition 0.000 description 1
- 238000002600 positron emission tomography Methods 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 108010074732 preproenkephalin Proteins 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 239000000007 protein synthesis inhibitor Substances 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940001470 psychoactive drug Drugs 0.000 description 1
- 239000004089 psychotropic agent Substances 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 229950010131 puromycin Drugs 0.000 description 1
- 210000002637 putamen Anatomy 0.000 description 1
- ZUFQODAHGAHPFQ-UHFFFAOYSA-N pyridoxine hydrochloride Chemical compound Cl.CC1=NC=C(CO)C(CO)=C1O ZUFQODAHGAHPFQ-UHFFFAOYSA-N 0.000 description 1
- 229940048084 pyrophosphate Drugs 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- FTSUPYGMFAPCFZ-ZWNOBZJWSA-N quinpirole Chemical compound C([C@H]1CCCN([C@@H]1C1)CCC)C2=C1C=NN2 FTSUPYGMFAPCFZ-ZWNOBZJWSA-N 0.000 description 1
- 229950001037 quinpirole Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000012950 reanalysis Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000003938 response to stress Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000003660 reticulum Anatomy 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- CXYRUNPLKGGUJF-RAFJPFSSSA-M scopolamine methobromide Chemical compound [Br-].C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)C)=CC=CC=C1 CXYRUNPLKGGUJF-RAFJPFSSSA-M 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 230000010332 selective attention Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000004905 short-term response Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 238000002603 single-photon emission computed tomography Methods 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 230000004006 stereotypic behavior Effects 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 230000002739 subcortical effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 235000021147 sweet food Nutrition 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000005062 synaptic transmission Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 208000027100 transient tic disease Diseases 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 229950009811 ubenimex Drugs 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012315 univariate regression analysis Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 208000029257 vision disease Diseases 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- 238000007794 visualization technique Methods 0.000 description 1
- 230000010330 visuo-spatial memory Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- QYSXJUFSXHHAJI-YRZJJWOYSA-N vitamin D3 Chemical compound C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C\C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-YRZJJWOYSA-N 0.000 description 1
- 235000005282 vitamin D3 Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 229940021056 vitamin d3 Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical group 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 238000004260 weight control Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Inorganic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Anesthesiology (AREA)
- Microbiology (AREA)
- Child & Adolescent Psychology (AREA)
- Diabetes (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4439497P | 1997-04-29 | 1997-04-29 | |
| US60/044,394 | 1997-04-29 | ||
| PCT/US1998/008684 WO1998048785A2 (en) | 1997-04-29 | 1998-04-29 | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JP2002511850A true JP2002511850A (ja) | 2002-04-16 |
Family
ID=21932148
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP54736498A Pending JP2002511850A (ja) | 1997-04-29 | 1998-04-29 | 報酬欠損症候群の対立遺伝子多遺伝子診断および処置 |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP0979092A2 (zh) |
| JP (1) | JP2002511850A (zh) |
| KR (1) | KR20010020422A (zh) |
| CN (1) | CN1261801A (zh) |
| AU (1) | AU7267798A (zh) |
| CA (1) | CA2288990A1 (zh) |
| IL (1) | IL132634A0 (zh) |
| IS (1) | IS5233A (zh) |
| NO (1) | NO995257L (zh) |
| WO (1) | WO1998048785A2 (zh) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2013047912A1 (ja) * | 2011-09-30 | 2015-03-30 | 公益財団法人東京都医学総合研究所 | サイクリックａｍｐ応答配列結合タンパク質遺伝子解析による薬物感受性および疾患脆弱性の評価方法 |
| JP2015067581A (ja) * | 2013-09-30 | 2015-04-13 | 国立大学法人京都大学 | 多重共鳴用のプローブ |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6622036B1 (en) * | 2000-02-09 | 2003-09-16 | Cns Response | Method for classifying and treating physiologic brain imbalances using quantitative EEG |
| US6132724A (en) * | 1998-04-29 | 2000-10-17 | City Of Hope National Medical Center | Allelic polygene diagnosis of reward deficiency syndrome and treatment |
| US6955873B1 (en) * | 2000-08-04 | 2005-10-18 | Kenneth Blum | Diagnosis and treatment system for reward deficiency syndrome (RDS) and related behaviors |
| GB9927806D0 (en) | 1999-11-24 | 2000-01-26 | Isis Innovation | Genetic indicators of tobacco consumption |
| ES2266008T3 (es) * | 2000-12-01 | 2007-03-01 | Be Able, Llc | Quimioterapia de comportamiento. |
| ITRM20010218A1 (it) * | 2001-04-23 | 2002-10-23 | Sigma Tau Healthscience Spa | Composizione per la prevenzione o il trattamento dei disturbi dell'apprendimento in bambini affetti da deficit dell'attenzione ed iperattivi |
| US8142800B1 (en) * | 2001-12-18 | 2012-03-27 | Tamea Rae Sisco | Oral high potency clinical anti-craving treatment and method of use |
| US8142799B2 (en) * | 2001-12-18 | 2012-03-27 | Tamea Rae Sisco | High potency clinical anti-craving treatment and method of use |
| JP5265923B2 (ja) * | 2005-02-07 | 2013-08-14 | ジーンニュース インコーポレーテッド | 軽度の変形性関節症のバイオマーカーおよびその使用 |
| WO2008038710A1 (fr) | 2006-09-28 | 2008-04-03 | Mitsubishi Electric Corporation | Détecteur de défauts, procédé et programme de détection de défauts |
| US20090318520A1 (en) * | 2008-06-20 | 2009-12-24 | Afecta Pharmaceuticals Drive | Use of isoindoles for the treatment of neurobehavioral disorders |
| AU2009259887A1 (en) * | 2008-06-21 | 2009-12-23 | B. William Downs | DNA-directed customization of analgesic compounds as a therapeutic modality |
| WO2010005303A2 (en) * | 2008-07-07 | 2010-01-14 | Publiekrechtelijke Rechtspersoon Academisch Ziekenhuis Leiden H.O.D.N. Leids Universitair Medisch Centrum | New indicators of human longevity and biological ageing rate |
| US9549708B2 (en) | 2010-04-01 | 2017-01-24 | Ecole Polytechnique Federale De Lausanne | Device for interacting with neurological tissue and methods of making and using the same |
| EP2585824A4 (en) * | 2010-04-22 | 2014-01-01 | Kenber Llc | ANALYSIS OF GENETIC RISK IN REWARDS DEFICIT SYNDROME |
| US11311718B2 (en) | 2014-05-16 | 2022-04-26 | Aleva Neurotherapeutics Sa | Device for interacting with neurological tissue and methods of making and using the same |
| CN103990106A (zh) * | 2014-06-11 | 2014-08-20 | 河北医科大学 | 八肽胆囊收缩素在制药中的应用 |
| US9925376B2 (en) * | 2014-08-27 | 2018-03-27 | Aleva Neurotherapeutics | Treatment of autoimmune diseases with deep brain stimulation |
| US9474894B2 (en) | 2014-08-27 | 2016-10-25 | Aleva Neurotherapeutics | Deep brain stimulation lead |
| CN104846015B (zh) * | 2015-05-27 | 2018-03-27 | 深圳先进技术研究院 | 特异性兴奋伏隔核中的gaba能神经元的组合物及其在改善精神分裂症异样行为中的应用 |
| US11464756B1 (en) | 2017-05-19 | 2022-10-11 | Jerry Darm | Mecuna pruriens, L-DOPA and 5-HTP based dietary supplements, pharmaceutical formulations and uses thereof |
| US10702692B2 (en) | 2018-03-02 | 2020-07-07 | Aleva Neurotherapeutics | Neurostimulation device |
| DE102018114364A1 (de) * | 2018-06-15 | 2019-12-19 | Susanne Koch | Verfahren und Vorrichtungen zur Bereitstellung eines Parameters, der auf eine erhöhte Wahrscheinlichkeit des Auftretens eines postoperativen Delirs hinweist |
| CN109316196B (zh) * | 2018-12-12 | 2022-07-19 | 上海市精神卫生中心（上海市心理咨询培训中心） | 基于虚拟现实联合脑电监测的苯丙胺类兴奋剂渴求评估方法 |
| CN110507294B (zh) * | 2019-08-07 | 2022-02-08 | 北京安龙脉德医学科技有限公司 | 基于互联网信息传递的急救系统 |
| CN110991044B (zh) * | 2019-12-03 | 2023-02-24 | 北京机电工程研究所 | 基于Agent建模的飞行器系统任务可靠性评估方法 |
| CN112862751B (zh) * | 2020-12-30 | 2022-05-31 | 电子科技大学 | 一种用于自闭症的自动诊断装置 |
| CN113332299A (zh) * | 2021-05-27 | 2021-09-03 | 广东湛江海洋医药研究院 | 红景天苷在缓解糖皮质激素性骨质疏松症中的应用 |
| KR102434668B1 (ko) * | 2022-03-02 | 2022-08-22 | 주식회사 국개대표 | 분리 불안 증상을 개선할 수 있는 반려동물용 사료 및 그 제조방법 |
| CN115830001B (zh) * | 2022-12-22 | 2023-09-08 | 抖音视界有限公司 | 肠道图像处理方法、装置、存储介质及电子设备 |
| CN116820166B (zh) * | 2023-06-08 | 2024-07-19 | 武汉汉联智控科技有限公司 | 一种高低温控温控流量系统及方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5189064A (en) * | 1985-07-22 | 1993-02-23 | Matrix Technologies, Inc. | Treatment of cocaine addiction |
| US4761429A (en) * | 1985-07-22 | 1988-08-02 | Kenneth Blum | Enkephalinase and endorphinase inhibitors as anti-craving compositions |
| US5013752A (en) * | 1989-03-10 | 1991-05-07 | Dobbins John P | Prevention and treatment of alcoholism by the use of dietary chromium |
| US5019594A (en) * | 1989-11-28 | 1991-05-28 | Interneuron Pharmaceuticals, Inc. | Method for decreasing appetite |
| US5164384A (en) * | 1991-06-19 | 1992-11-17 | Metagenics, Inc. | Anabolic mineral formula |
| US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
-
1998
- 1998-04-29 IL IL13263498A patent/IL132634A0/xx unknown
- 1998-04-29 AU AU72677/98A patent/AU7267798A/en not_active Abandoned
- 1998-04-29 KR KR1019997010047A patent/KR20010020422A/ko not_active Application Discontinuation
- 1998-04-29 CA CA002288990A patent/CA2288990A1/en not_active Abandoned
- 1998-04-29 WO PCT/US1998/008684 patent/WO1998048785A2/en not_active Application Discontinuation
- 1998-04-29 CN CN98806484A patent/CN1261801A/zh active Pending
- 1998-04-29 EP EP98920019A patent/EP0979092A2/en not_active Withdrawn
- 1998-04-29 JP JP54736498A patent/JP2002511850A/ja active Pending
-
1999
- 1999-10-28 IS IS5233A patent/IS5233A/is unknown
- 1999-10-28 NO NO995257A patent/NO995257L/no not_active Application Discontinuation
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2013047912A1 (ja) * | 2011-09-30 | 2015-03-30 | 公益財団法人東京都医学総合研究所 | サイクリックａｍｐ応答配列結合タンパク質遺伝子解析による薬物感受性および疾患脆弱性の評価方法 |
| US9727691B2 (en) | 2011-09-30 | 2017-08-08 | Tokyo Metropolitan Institute Of Medical Science | Method for evaluating drug sensitivity and disease vulnerability by analyzing cyclic AMP responsive element binding protein gene |
| JP2015067581A (ja) * | 2013-09-30 | 2015-04-13 | 国立大学法人京都大学 | 多重共鳴用のプローブ |
Also Published As
| Publication number | Publication date |
|---|---|
| AU7267798A (en) | 1998-11-24 |
| IS5233A (is) | 1999-10-28 |
| CA2288990A1 (en) | 1998-11-05 |
| NO995257D0 (no) | 1999-10-28 |
| WO1998048785A9 (en) | 1999-05-20 |
| EP0979092A2 (en) | 2000-02-16 |
| WO1998048785A2 (en) | 1998-11-05 |
| NO995257L (no) | 1999-12-27 |
| WO1998048785A3 (en) | 1999-04-01 |
| KR20010020422A (ko) | 2001-03-15 |
| IL132634A0 (en) | 2001-03-19 |
| CN1261801A (zh) | 2000-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002511850A (ja) | 報酬欠損症候群の対立遺伝子多遺伝子診断および処置 | |
| US6132724A (en) | Allelic polygene diagnosis of reward deficiency syndrome and treatment | |
| JP7532465B2 (ja) | 注意欠陥障害及び２２ｑ症候群の治療のための非選択的代謝型グルタメート受容体アクチベーター | |
| Blum et al. | The reward deficiency syndrome: a biogenetic model for the diagnosis and treatment of impulsive, addictive and compulsive behaviors | |
| Blum et al. | Neurogenetics of dopaminergic receptor supersensitivity in activation of brain reward circuitry and relapse: proposing “deprivation-amplification relapse therapy”(DART) | |
| Miller et al. | Acute intravenous synaptamine complex variant KB220™“normalizes” neurological dysregulation in patients during protracted abstinence from alcohol and opiates as observed using quantitative electroencephalographic and genetic analysis for reward polymorphisms: part 1, pilot study with 2 case reports | |
| JP2011528321A (ja) | ニュートリゲノミクス方法および組成 | |
| US11324723B2 (en) | Molecular genetic approach to treatment and diagnosis of alcohol and drug dependence | |
| Pascucci et al. | 5-Hydroxytryptophan rescues serotonin response to stress in prefrontal cortex of hyperphenylalaninaemic mice | |
| CA2494585A1 (en) | Methods for the treatment of dementia based on apo e genotype | |
| Pettinati et al. | Recent advances in the treatment of alcoholism | |
| de Rijk | Epidemiology of Parkinson's disease: the Rotterdam Study | |
| Blum et al. | Neurogenetics and nutrigenomics of Reward Deficiency Syndrome (RDS): Stratification of addiction risk and mesolimbic nutrigenomic manipulation of hypodopaminergic function | |
| JP2022529179A (ja) | 注意欠陥多動性障害の遺伝的リスク分析及びその行動管理 | |
| MXPA99009902A (en) | Allelic polygene diagnosis of reward deficiency syndrome and treatment | |
| Hallikainen | Serotonin and dopamine gene polymorphisms and alcohol consumption | |
| Setiawan | Individual differences in the neurobiology of responses to alcohol in humans | |
| Sanci | The central serotonin system in depressed alcoholics: response to tryptophan depletion and influence of a serotonin transporter polymorphism. | |
| Blum et al. | Nutrigenomics of Neuradaptogen Amino-Acid-Therapy and Neurometabolic Optimizers: Overcoming carbohydrate bingeing and overeating through neurometabolic mechanisms | |
| Maili | Cocaine Dependence: The Role Of Serotonin Genes In | |
| NADU | POLYMORPHISMS IN THE DOPAMINE RECEPTOR 4 GENE: IS THERE AN ASSOCIATION WITH CLINICAL RESPONSE TO CLOZAPINE IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA?! | |
| Singer | OPENING TALK | |
| SUNDAY | 1. MOLECULAR GENETICS AND BIOLOGY a. Human-association b. Human-other | |
| Tjan-Heijnen et al. | Age-Related Memory Decline and the APOE ε4 Effect | |
| Diaz Anzaldua | Genetic investigation of Tourette syndrome in the French Canadian population |